- Home
- MBIO vs APM Comparison
MBIO vs APM Comparison
Compare MBIO & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- APM
- Stock Information
- Founded
- MBIO 2015
- APM 2010
- Country
- MBIO United States
- APM United Kingdom
- Employees
- MBIO N/A
- APM N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- MBIO Health Care
- APM Health Care
- Exchange
- MBIO Nasdaq
- APM Nasdaq
- Market Cap
- MBIO 7.3M
- APM 6.1M
- IPO Year
- MBIO N/A
- APM 2018
- Fundamental
- Price
- MBIO $1.24
- APM $1.07
- Analyst Decision
- MBIO
- APM
- Analyst Count
- MBIO 0
- APM 0
- Target Price
- MBIO N/A
- APM N/A
- AVG Volume (30 Days)
- MBIO 102.4K
- APM 81.2K
- Earning Date
- MBIO 05-14-2025
- APM 06-17-2025
- Dividend Yield
- MBIO N/A
- APM N/A
- EPS Growth
- MBIO N/A
- APM N/A
- EPS
- MBIO N/A
- APM N/A
- Revenue
- MBIO N/A
- APM N/A
- Revenue This Year
- MBIO N/A
- APM N/A
- Revenue Next Year
- MBIO N/A
- APM N/A
- P/E Ratio
- MBIO N/A
- APM N/A
- Revenue Growth
- MBIO N/A
- APM N/A
- 52 Week Low
- MBIO $1.01
- APM $0.46
- 52 Week High
- MBIO $65.00
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- MBIO 47.58
- APM 58.89
- Support Level
- MBIO $1.25
- APM $0.83
- Resistance Level
- MBIO $1.34
- APM $1.35
- Average True Range (ATR)
- MBIO 0.07
- APM 0.12
- MACD
- MBIO 0.01
- APM 0.02
- Stochastic Oscillator
- MBIO 61.54
- APM 46.97
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.